The US Phase III trial of the drug was a success.
Globes' correspondent (11 Oct 09)

 

Drug developer Kamada Ltd. (TASE: KMDA) today announced that it is beginning the Phase II/III clinical trial in Europe of inhalable alpha-1 antitrypsin (AAT) for the treatment hereditary emphysema. The trial will begin at sites in the Netherlands during the fourth quarter of 2009.

The European Medicines Agency (EMEA) and the Dutch Central Committee on Research Involving Human Subjects (CCMO) has approved the trial protocol.